View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
HHS/FDA | RIN: 0910-AH53 | Publication ID: Spring 2021 |
Title: Medical Device De Novo Classification Process | |
Abstract:
De Novo classification decreases regulatory burdens because manufacturers can use a less burdensome application pathway under the FD&C Act to market certain devices. The rule would establish procedures and criteria for the De Novo process and would make it more transparent and predictable for manufacturers. By clarifying and making more efficient the De Novo request requirements, we expect the rule would reduce the time and costs associated with reviewing De Novo requests and generate net benefits in the form of cost savings. |
|
Agency: Department of Health and Human Services(HHS) | Priority: Other Significant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Final Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 860 | |
Legal Authority: 21 U.S.C. 321(h) 21 U.S.C. 360c, 360i-360j 21 U.S.C. 371 21 U.S.C. 374 |
Legal Deadline:
None |
||||||||||||
Timetable:
|
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: No | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Data Printed in the FR: No | |
Agency Contact: Laurie Sternberg Regulatory Counsel Department of Health and Human Services Food and Drug Administration Suite 200N (HFM-630), 10903 New Hampshire Avenue, Building 66, Room 5517, Silver Spring, MD 20993 Phone:240 402-0425 Email: laurie.sternberg@fda.hhs.gov |